



Tyrosine Kinase Inhibitors (TKIs) in Gastro-Intestinal Cancers

From Bench to Bedside and Future Directions in development.

Friday, 3 July 2020

12:15

CHAIR

Scott Kopetz
Houston, TX, USA

This educational activity is provided by ESMO
and supported by Bayer.

12:15

Welcome and introduction

Scott Kopetz, Houston, TX, USA

12:20

The mechanistic rationale of different TKIs

Scott Kopetz, Houston, TX, USA

12:35

**The evolving role of TKIs in multi-line
treatment of metastatic colorectal cancers**

Julien Taieb, Paris, France

12:50

**Positioning TKIs in the treatment of
Advanced Hepato-Cellular Carcinoma:
Is there a preferred sequence?**

Sherrie Bhoori, Milan, Italy

13:05

Conclusions: Take home messages

Scott Kopetz, Houston, TX, USA